Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer
EstadísticasView Usage Statistics
Full recordShow full item record
AuthorAguilera, Óscar; González Sancho, José Manuel; Zazo Hernández, Sandra; Rincón, Raúl; Fernández Fernández, Agustín; Tapia Martínez, Olga; Canals, Francesc; Morte Molina, Beatriz; Calvanese, Vincenzo; Orgaz Bueno, José Luis; Niell Garolera, Núria; Aguilar, Susana; Freije, José M.; Graña, Osvaldo; Pisano, David G.; Borrero Palacios, Aurea; Martínez Useros, Javier; Jiménez Cuenca, Benilde; Fernández Fraga, Mario; [et al.]
Atribución 3.0 España
Oncotarget. 2015 Mar 20;6(8):5903-17
Sporadic colorectal cancer (CRC) insurgence and progression depend on the activation of Wnt/β-catenin signaling. Dickkopf (DKK)-1 is an extracellular inhibitor of Wnt/β-catenin signaling that also has undefined β-catenin-independent actions. Here we report for the first time that a proportion of DKK-1 locates within the nucleus of healthy small intestine and colon mucosa, and of CRC cells at specific chromatin sites of active transcription. Moreover, we show that DKK-1 regulates several cancer-related genes including the cancer stem cell marker aldehyde dehydrogenase 1A1 (ALDH1A1) and Ral-binding protein 1-associated Eps domain-containing 2 (REPS2), which are involved in detoxification of chemotherapeutic agents. Nuclear DKK-1 expression is lost along CRC progression; however, it remains high in a subset (15%) of CRC patients (n = 699) and associates with decreased progression-free survival (PFS) after chemotherapy administration and overall survival (OS) [adjusted HR, 1.65; 95% confidence interval (CI), 1.23-2.21; P = 0.002)]. Overexpression of ALDH1A1 and REPS2 associates with nuclear DKK-1 expression in tumors and correlates with decreased OS (P = 0.001 and 0.014) and PFS. In summary, our findings demonstrate a novel location of DKK-1 within the cell nucleus and support a role of nuclear DKK-1 as a predictive biomarker of chemoresistance in colorectal cancer.